Vaxcyte Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Vaxcyte
PCVX Stock  USD 86.53  0.32  0.37%   
Vaxcyte financial statements provide useful quarterly and yearly information to potential Vaxcyte investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vaxcyte financial statements helps investors assess Vaxcyte's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vaxcyte's valuation are summarized below:
Gross Profit
-23 M
Market Capitalization
10.8 B
Earnings Share
(4.60)
We have found one hundred twenty available fundamental trend indicators for Vaxcyte, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vaxcyte current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 1.5 B in 2024. Enterprise Value is likely to drop to about 1.2 B in 2024
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Vaxcyte Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.5 B1.4 B337.5 M
Slightly volatile
Other Current Liabilities122.4 M116.5 M20.3 M
Slightly volatile
Total Current Liabilities152.6 M145.3 M31.1 M
Slightly volatile
Other Liabilities7.7 K8.1 K159.8 K
Slightly volatile
Accounts Payable10.8 M14.6 M6.2 M
Slightly volatile
Cash290.5 M397.5 M159.5 M
Slightly volatile
Other Assets0.951.0982.1 K
Slightly volatile
Long Term Debt384.8 K405 K2.4 M
Slightly volatile
Cash And Short Term Investments1.1 B1.1 B279.5 M
Slightly volatile
Common Stock Shares Outstanding57.4 M97.2 M40.1 M
Slightly volatile
Long Term Debt Total384.8 K405 K2.4 M
Slightly volatile
Capital Surpluse703.8 M670.3 M206.1 M
Slightly volatile
Total Liabilities96.9 M167.4 M51.6 M
Slightly volatile
Total Current Assets1.2 B1.1 B283.6 M
Slightly volatile
Common Stock102.9 K98 K30.3 K
Slightly volatile
Property Plant Equipment38.2 M36.4 M11.7 M
Slightly volatile
Short and Long Term Debt Total15.1 M29.2 M8.8 M
Slightly volatile
Property Plant And Equipment Net116.2 M110.6 M22.1 M
Slightly volatile
Non Current Assets Total327.6 M312 M54.4 M
Slightly volatile
Non Currrent Assets Other40.6 M38.7 M6.5 M
Slightly volatile
Common Stock Total Equity33.8 K64.4 K21.7 K
Slightly volatile
Liabilities And Stockholders Equity1.5 B1.4 B354.2 M
Slightly volatile
Non Current Liabilities Total43.8 M22.1 M89.8 M
Slightly volatile
Other Current Assets16.5 M15.7 M3.8 M
Slightly volatile
Other Stockholder Equity2.3 B2.2 B445.2 M
Slightly volatile
Capital Stock55.5 K98 K27.1 K
Slightly volatile
Non Current Liabilities Other7.7 K8.1 K2 M
Slightly volatile
Net Working Capital998.1 M950.6 M267.4 M
Slightly volatile
Short Term Debt8.2 M14.2 M3.9 M
Slightly volatile
Net Receivables3.8 M3.6 M793 K
Slightly volatile
Property Plant And Equipment Gross162.3 M154.6 M30.7 M
Slightly volatile
Deferred Long Term Liabilities403.3 K575 K205.2 K
Slightly volatile

Vaxcyte Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income66.1 M62.9 M9.4 M
Slightly volatile
Selling General Administrative63.7 M60.7 M17.3 M
Slightly volatile
Net Interest Income66.1 M62.9 M9.7 M
Slightly volatile
Depreciation And Amortization4 M3.2 M2.3 M
Slightly volatile
Other Operating Expenses491.4 M468 M115.3 M
Slightly volatile
Research Development349 M332.3 M88 M
Slightly volatile
Total Operating Expenses491.4 M468 M115.3 M
Slightly volatile
Reconciled Depreciation10.7 M10.2 M3 M
Slightly volatile
Total Other Income Expense Net69.1 M65.8 M13.2 M
Slightly volatile
Cost Of Revenue78.8 M75 M11.9 M
Slightly volatile
Non Operating Income Net Other2.2 M4.1 M1.2 M
Slightly volatile
Selling And Marketing Expenses8.1 M9.2 M10 M
Slightly volatile

Vaxcyte Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.9 M2 M30.9 M
Slightly volatile
Stock Based Compensation51.2 M48.8 M9.4 M
Slightly volatile
Begin Period Cash Flow877.3 M835.5 M155.3 M
Slightly volatile
Depreciation10.7 M10.2 M2.5 M
Slightly volatile
Capital Expenditures71.3 M67.9 M10.4 M
Slightly volatile
Total Cash From Financing Activities671.8 M639.8 M178 M
Slightly volatile
End Period Cash Flow285.3 M398.6 M140 M
Slightly volatile
Change To Account Receivables853.6 K781.2 K1.1 M
Slightly volatile
Issuance Of Capital Stock364.6 M636 M190.1 M
Slightly volatile
Dividends Paid299.2 K336.6 K366.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation7.016.67362.3573
Slightly volatile
Payables Turnover5.45.14161.0304
Slightly volatile
Cash Per Share5.9111.11838.5713
Pretty Stable
Days Payables Outstanding67.4470.99011.3 K
Very volatile
Income Quality0.960.73780.8741
Very volatile
Net Debt To EBITDA0.750.79211.9091
Very volatile
Current Ratio8.247.54079.333
Pretty Stable
Graham Number36.2134.487626.5349
Pretty Stable
Debt To Equity0.00540.00570.0709
Slightly volatile
Capex Per Share0.730.69860.1176
Slightly volatile
Interest Debt Per Share0.06960.07320.5851
Slightly volatile
Debt To Assets0.00480.00510.056
Slightly volatile
Days Of Payables Outstanding67.4470.99011.3 K
Very volatile
Ebt Per Ebit1.020.85950.9529
Pretty Stable
Long Term Debt To Capitalization0.0880.09750.1063
Slightly volatile
Total Debt To Capitalization0.00540.00570.0638
Slightly volatile
Debt Equity Ratio0.00540.00570.0709
Slightly volatile
Quick Ratio8.257.54079.3397
Pretty Stable
Net Income Per E B T0.820.971.0325
Slightly volatile
Cash Ratio2.62.73477.9716
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.861.22871.0626
Slightly volatile
Debt Ratio0.00480.00510.056
Slightly volatile

Vaxcyte Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.5 B2.8 B1.6 B
Slightly volatile
Enterprise Value1.2 B2.1 B1.2 B
Slightly volatile

Vaxcyte Fundamental Market Drivers

Cash And Short Term Investments1.1 B

Vaxcyte Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-107.7 M-102.3 M
Cost Of Revenue75 M78.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY